ChronoScale to Divest Ekso Bionics Subsidiary, Focus on Cloud Business
CHRN has more than doubled off its 52-week low of $2.73 on elevated volume (3.2× avg).
Summary
ChronoScale Corp is divesting its Ekso Bionics subsidiary to focus solely on its cloud business, a strategic move under its new controlling parent, Applied Digital Corporation, which is expected to result in material exit costs.
Key Events · M&A and Partnerships · CHRN
-
Strategic Divestiture Announced
The Board committed to divesting its wholly owned subsidiary, Ekso Bionics, Inc., to focus operations solely on its cloud business.
-
Material Exit Costs Expected
The company anticipates incurring material charges, including severance and lease termination payments, though specific estimates are not yet available.
-
Follows Recent Acquisition
This strategic shift occurs shortly after Applied Digital Corporation acquired a 97.5% controlling stake in ChronoScale Corp on May 13, 2026.
Analysis · CHRN · Technology
The company's Board has approved a plan to sell its Ekso Bionics subsidiary, shifting its entire operational focus to the cloud business. This strategic realignment follows the recent acquisition of a 97.5% stake by Applied Digital Corporation. While the move aims to streamline operations, it is expected to incur material charges, including severance and lease termination costs, the exact amount of which will be disclosed in a future amendment.
At the time of this filing, CHRN was trading at $23.31 on NASDAQ in the Technology sector, with a market capitalization of approximately $83.2M. The 52-week trading range was $2.73 to $23.36. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.